Nutriband Inc. (NTRBW)
NCM
$0.35
-33.96%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Exchange
NCM
Currency
USD
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Quarterly Financials
| Metric | 2025-07-31 | 2025-10-31 | 2026-01-31 | 2026-04-30 |
|---|---|---|---|---|
| Revenue | 622K | 346K | 401K | 433K |
| Gross Profit | 157K | 69K | 89K | 197K |
| Operating Income | -2.0M | -3.9M | -1.0M | -1.3M |
| Net Income | -2.0M | -3.9M | -968K | -1.2M |
Annual Financials
| Metric | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2026-01-31 |
|---|---|---|---|---|
| Revenue | 2.1M | 2.1M | 2.1M | 2.0M |
| Gross Profit | 750K | 862K | 743K | 566K |
| Operating Income | -4.1M | -4.9M | -6.7M | -8.3M |
| Net Income | -4.5M | -5.5M | -10.5M | -8.2M |